Drug Search Results
More Filters [+]

Nadifloxacin

Alternative Names: nadifloxacin, nadifloxacine, Acuatim, Nadiflox, Nadoxin, Nadixa, Activon
Latest Update: 2024-02-08
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: TOP2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Algeria | Australia | Austria | Brazil | Colombia | Dominican Republic | Egypt | Germany | Hungary | India | Indonesia | Italy | Jordan | Korea | Lebanon | Malaysia | Mexico | Pakistan | Peru | Philippines | Portugal | South Africa | Spain | Taiwan | Turkey | United Arab Emirates | United Kingdom | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Kuopio University Hospital
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nadifloxacin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Acne Vulgaris|Pressure Ulcer|Chronic Pain|Labor Pain|Environmental Hypersensitivity|Acute Pain

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MICAREA

P3

Not yet recruiting

Acute Pain|Labor Pain|Chronic Pain|Environmental Hypersensitivity|Pressure Ulcer

2026-01-01

mar-der1

P3

Unknown status

Acne Vulgaris

2009-06-01

Recent News Events